Valuation : Abivax

Market Cap 9.11B 10.58B 8.54B 7.8B 14.69B 1,011B 14.74B 101B 39.55B 510B 39.71B 38.84B 1,692B P/E 2026 *
-27.5x
P/E 2027 * -32.3x
Enterprise Value 8.01B 9.3B 7.51B 6.86B 12.92B 888B 12.96B 89.11B 34.77B 448B 34.9B 34.14B 1,487B EV / Sales 2026 *
107x
EV / Sales 2027 * 98.1x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day-1.03%
1 week-1.73%
Current month-9.31%
1 month-9.31%
3 months-13.77%
6 months+1.05%
Current year-19.93%
1 week 96.15
Extreme 96.15
104.2
1 month 96.15
Extreme 96.15
115.8
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.9
Extreme 3.9
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Exercice

Chief Executive Officer

17,728 0.0222%
7/11/26 Exercice

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%-1.73%+43.03%+450.86% 10.58B
-0.94%-1.74%+1.16%+18.14% 50.47B
-2.43%-4.05%+413.56%+497.62% 44.56B
-0.79%-0.87%+40.41%+15.88% 43.08B
-2.96%-4.35%+7.16%+71.43% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.13%-4.92%+24.54%+118.12% 16.77B
+5.81%+5.06% - - 16.28B
-0.28%-1.50%+11.05%+26.95% 14.58B
-0.68%-3.55%+78.60%+39.25% 13.92B
Average -0.35%-1.68%+71.00%+142.94% 28.51B
Weighted average by Cap. -0.86%-1.32%+86.64%+134.05%

Financials

2026 *2027 *
Net sales 74.92M 86.95M 70.25M 64.13M 121M 8.31B 121M 833M 325M 4.19B 326M 319M 13.91B 82.73M 96.01M 77.57M 70.81M 133M 9.18B 134M 920M 359M 4.63B 360M 353M 15.36B
Net income -265M -308M -249M -227M -427M -29.41B -429M -2.95B -1.15B -14.84B -1.16B -1.13B -49.22B -231M -268M -216M -197M -372M -25.59B -373M -2.57B -1B -12.92B -1.01B -983M -42.84B
Net Debt -1.1B -1.28B -1.03B -944M -1.78B -122B -1.78B -12.26B -4.79B -61.73B -4.8B -4.7B -205B -993M -1.15B -931M -850M -1.6B -110B -1.61B -11.04B -4.31B -55.57B -4.32B -4.23B -184B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-08-31 96.40 -1.03% 30,425
26-08-28 €97.40 -2.55% 127,732
26-08-27 €99.95 -0.45% 85,504
26-08-26 €100.40 -1.86% 100,533
26-08-25 €102.30 +4.28% 190,081
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
97.40EUR
Average target price
138.97EUR
Spread / Average Target
+42.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock